United States

Key Developments: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

27 May 2016
Change (% chg)

$0.01 (+0.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sequenom, Inc Announces contract with Anthem BlueCross
Wednesday, 2 Mar 2016 04:39pm EST 

Sequenom, Inc:Announces contract with antheAnnounces Contract with Anthem BlueCrossm bluecross.  Full Article

Sequenom Inc. Announces Restructuring: Plans Sale Of North Carolina Operations And Initiatives To Improve Efficiencies
Thursday, 7 Jan 2016 02:43pm EST 

Sequenom Inc :Announces restructuring: plans sale of North Carolina operations and initiatives to improve efficiencies.Says intends to sell its operations in Research Triangle Park, North Carolina.Says operations currently conducted in North Carolina will be consolidated in San Diego throughout the first half of 2016.Says plans to divest sequenom's North Carolina operations.Says will also seek strategic partners for the commercialization of its oncology liquid biopsy assay.Says will reduce its workforce by approximately 20%, or 110 positions.Increased expected cost savings of over $10 million annually to annualized cost savings anticipated to exceed $20 million in late 2016.Says reductions are planned in both the cost of revenues and in operating expenses, primarily in research and development.Says announced its goal of attaining a neutral operating cash flow run rate before the end of 2017.  Full Article

Sequenom Inc collaborates with University Medical Center Hamburg-eppendorf to evaluate clinical utility of liquid biopsy in colorectal cancer
Monday, 12 Oct 2015 07:00am EDT 

Sequenom Inc:Has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf in Germany.University Medical Center Hamburg-Eppendorf and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients.  Full Article

Sequenom Inc gives H2 2015 revenue guidance; gives FY 2015 revenue guidance below analysts' estimates
Friday, 25 Sep 2015 07:00am EDT 

Sequenom Inc:Updates its revenue expectations for H2 2015 to a range between $57 million and $61 million, bringing 2015 annual revenue expectations to a range between $127 million and $131 million.Q3 2015 revenue of $35 million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $35.6 million - Thomson Reuters I/B/E/S.FY 2015 revenue of $141 million - Thomson Reuters I/B/E/S.  Full Article

Sequenom Inc Announces Appointment of Dirk van den Boom as Interim President and CEO
Monday, 21 Sep 2015 07:00am EDT 

Sequenom Inc:Announced today the appointment of Dirk van den Boom, Ph.D. to the position of interim President and Chief Executive Officer. Dr. van den Boom succeeds William J. Welch following his resignation from that role, and as a director, to pursue other interests.In addition, Dr. van den Boom will continue to serve as Sequenom's Chief Scientific and Strategy Officer.  Full Article

Sequenom announces national coverage agreement with unitedhealthcare insurance company for prenatal diagnostic testing services
Thursday, 17 Sep 2015 07:00am EDT 

Sequenom:Press release - Sequenom Laboratories announces national coverage agreement with unitedhealthcare insurance company for prenatal diagnostic testing services.Says brings the number of covered lives under agreement by Sequenom laboratories' diagnostic services to more than 200 million.  Full Article

Sequenom changes in registrant’s certifying accountant - Form 8-K
Thursday, 25 Jun 2015 06:02am EDT 

Sequenom:On June 19, Company notified Ernst & Young LLP of its dismissal as the Company’s independent registered public accounting firm effective as of that date.On June 19, Company selected KPMG LLP as its new independent registered public accounting firm.  Full Article

Sequenom Inc's Sequenom Laboratories launches the HerediT UNIVERSAL Test in collaboration with Recombine
Thursday, 19 Mar 2015 05:30pm EDT 

Sequenom Laboratories:Says the launch of the HerediT UNIVERSAL carrier screening test as a service to ordering physicians.Launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.Current options are limited to single gene testing or tests that can identify about 100 hereditary conditions.This new offering can be performed preconception or at any time during pregnancy.Sequenom Laboratories is a wholly owned subsidiary of Sequenom Inc.  Full Article

Kenneth Buechler elected Chairman of Sequenom Inc Board of Directors
Tuesday, 17 Mar 2015 07:00am EDT 

Sequenom Inc:Board elected Kenneth Buechler as Chairman of Board, effective April 1.Says Buechler succeeds Harry Hixson, Jr. who will retire from position effective March 31, after 11 years of service.  Full Article

Sequenom Inc and Cypher Genomics Inc announce development agreement
Thursday, 22 Jan 2015 07:00am EST 

Sequenom Inc and Cypher Genomics Inc:Say a development agreement for next generation noninvasive prenatal tests (NIPT).Through this agreement, Sequenom will utilize Cypher's genome interpretation technology, called Mantis, to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood.Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with risks of morbidity and mortality.  Full Article

Roche tells Supreme Court no need to revisit Sequenom patent invalidation

Roche Holding AG has urged the U.S. Supreme Court not to overturn the precedents it has carefully developed over decades barring patents on natural laws and phenomena in response to a plea from Sequenom, Inc to save a patent on its prenatal DNA test from invalidation.